Altered distribution of RhoA in alzheimer's disease and AβPP overexpressing mice

dc.contributor.authorHuesa, Gema
dc.contributor.authorBaltrons, Maria Antonia
dc.contributor.authorGómez-Ramos, Pilar
dc.contributor.authorMorán, Asunción
dc.contributor.authorGarcía, Agustina
dc.contributor.authorHidalgo, Juan
dc.contributor.authorFrancés, Silvia
dc.contributor.authorSantpere Baró, Gabriel
dc.contributor.authorFerrer, Isidro (Ferrer Abizanda)
dc.contributor.authorGalea, Elena
dc.date.accessioned2020-04-14T08:55:36Z
dc.date.available2020-04-14T08:55:36Z
dc.date.issued2010
dc.date.updated2020-04-14T08:55:37Z
dc.description.abstractRhoGTPases control cytoskeleton dynamics thereby modulating synaptic plasticity. Because Alzheimer's disease (AD) is characterized by synaptic dysfunction, we sought to determine whether the expression, activity, or localization of the GTPases RhoA, Rac1 and Cdc42, as well as p21-PAK, a downstream target of Rac1/Cdc42, were altered in 18-month-old AbetaPP Tg2576 mice (Swedish mutation) or in brains from patients with AD and, for comparison in the case of RhoA, Pick's disease (PiD), a neurodegenerative disorder characterized by hyper-phosphorylated tau accumulation. Immunohistochemical analyses revealed a distinct localization of each RhoGTPase in synapses, dendrite shafts, neuronal bodies, or astrocytes. The association of RhoA with synapses and dendritic microtubules was confirmed by electron microscopy. In AbetaPP mice, RhoA expression decreased in synapses and increased in dystrophic neurites, suggesting altered subcellular targeting of RhoA. In AD, RhoA immunostaining decreased in the neuropil and markedly increased in neurons, co-localizing with hyperphosphorylated tau inclusions, as though RhoA were sequestered by neurofibrillary tangles. Additionally, total RhoA protein was lower in the AD brain hippocampus, reflecting loss of the membrane bound, presumably active, GTPase. RhoA colocalized with hyperphosphorylated tau in PiD, again suggesting that altered subcellular targeting of RhoA is related to neurodegeneration. No major immunohistochemical changes were observed for Rac1, Cdc42, or p21-PAK, thus identifying RhoA among RhoGTPases as a possible therapeutic target in AD.
dc.format.extent20 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec600951
dc.identifier.issn1387-2877
dc.identifier.pmid20061625
dc.identifier.urihttps://hdl.handle.net/2445/155221
dc.language.isoeng
dc.publisherIOS Press
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3233/JAD-2010-1203
dc.relation.ispartofJournal of Alzheimer's Disease, 2010, vol. 19, num. 1, p. 37-56
dc.relation.urihttps://doi.org/10.3233/JAD-2010-1203
dc.rights(c) Huesa, Gema et al., 2010
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject.classificationMalaltia d'Alzheimer
dc.subject.classificationMetabolisme
dc.subject.classificationAmiloïdosi
dc.subject.otherAlzheimer's disease
dc.subject.otherMetabolism
dc.subject.otherAmyloidosis
dc.titleAltered distribution of RhoA in alzheimer's disease and AβPP overexpressing mice
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
600951.pdf
Mida:
3.17 MB
Format:
Adobe Portable Document Format